Barbara H Braffett
What are the clinical, quality-of-life, and cost consequences of 30 years of excellent vs. poor glycemic control in type 1 diabetes?
Herman W, Braffett B, Kuo S, Lee J, Brändle M, Jacobson A, Prosser L, Lachin J. What are the clinical, quality-of-life, and cost consequences of 30 years of excellent vs. poor glycemic control in type 1 diabetes?. J Diabetes Complicat 2018; 32:911-915.
12.06.2018What are the clinical, quality-of-life, and cost consequences of 30 years of excellent vs. poor glycemic control in type 1 diabetes?
12.06.2018J Diabetes Complicat 2018; 32:911-915
Herman William H, Braffett Barbara H, Kuo Shihchen, Lee Joyce M, Brändle Michael, Jacobson Alan M, Prosser Lisa A, Lachin John M
The 30-year cost-effectiveness of alternative strategies to achieve excellent glycemic control in type 1 diabetes: An economic simulation informed by the results of the diabetes control and complications trial/epidemiology of diabetes interventions and complications (DCCT/EDIC)
Herman W, Braffett B, Kuo S, Lee J, Brändle M, Jacobson A, Prosser L, Lachin J. The 30-year cost-effectiveness of alternative strategies to achieve excellent glycemic control in type 1 diabetes: An economic simulation informed by the results of the diabetes control and complications trial/epidemiology of diabetes interventions and complications (DCCT/EDIC). J Diabetes Complicat 2018; 32:934-939.
12.06.2018The 30-year cost-effectiveness of alternative strategies to achieve excellent glycemic control in type 1 diabetes: An economic simulation informed by the results of the diabetes control and complications trial/epidemiology of diabetes interventions and complications (DCCT/EDIC)
12.06.2018J Diabetes Complicat 2018; 32:934-939
Herman William H, Braffett Barbara H, Kuo Shihchen, Lee Joyce M, Brändle Michael, Jacobson Alan M, Prosser Lisa A, Lachin John M